Literature DB >> 22441169

Neoplastic B-cell growth is impaired by HLA-G/ILT2 interaction.

A Naji, C Menier, G Maki, E D Carosella, N Rouas-Freiss.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22441169     DOI： 10.1038/leu.2012.62

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  26 in total

1.  Ig-like transcript 2 (ILT2) suppresses T cell function in chronic lymphocytic leukemia.

Authors:  Mónica Villa-Álvarez; Seila Lorenzo-Herrero; Ana P Gonzalez-Rodriguez; Alejandro López-Soto; Angel R Payer; Esther Gonzalez-Garcia; Leticia Huergo-Zapico; Segundo Gonzalez
Journal:  Oncoimmunology       Date:  2017-07-20       Impact factor: 8.110

Review 2.  Leukocyte immunoglobulin-like receptors in human diseases: an overview of their distribution, function, and potential application for immunotherapies.

Authors:  Jilu Zhang; Sunny Mai; Hui-Ming Chen; Kyeongah Kang; Xian Chang Li; Shu-Hsia Chen; Ping-Ying Pan
Journal:  J Leukoc Biol       Date:  2017-03-28       Impact factor: 4.962

3.  Human Leukocyte Antigen-G (HLA-G) Expression in Cancers: Roles in Immune Evasion, Metastasis and Target for Therapy.

Authors:  Aifen Lin; Wei-Hua Yan
Journal:  Mol Med       Date:  2015-08-24       Impact factor: 6.354

4.  HLA-G-ILT2 interaction contributes to suppression of bone marrow B cell proliferation in acquired aplastic anemia.

Authors:  Yuan-Xin Sun; Qi Feng; Shu-Wen Wang; Xin Li; Zi Sheng; Jun Peng
Journal:  Ann Hematol       Date:  2022-01-18       Impact factor: 3.673

5.  High plasma levels of HLA-G are associated with low birth weight and with an increased risk of malaria in infancy.

Authors:  Ibrahim Sadissou; Tania d'Almeida; Gilles Cottrell; Adrian Luty; Irène Krawice-Radanne; Achille Massougbodji; Philippe Moreau; Kabirou Moutairou; André Garcia; Benoit Favier; Nathalie Rouas-Freiss; David Courtin
Journal:  Malar J       Date:  2014-08-12       Impact factor: 2.979

6.  The paradox of high availability and low recognition of soluble HLA-G by LILRB1 receptor in rheumatoid arthritis patients.

Authors:  Tiago Degani Veit; José Artur Bogo Chies; Magdalena Switala; Bettina Wagner; Peter A Horn; Mauricio Busatto; Claiton Viegas Brenol; João Carlos Tavares Brenol; Ricardo Machado Xavier; Vera Rebmann
Journal:  PLoS One       Date:  2015-04-08       Impact factor: 3.240

7.  Comprehensive Transcriptomic Analysis Reveals the Role of the Immune Checkpoint HLA-G Molecule in Cancers.

Authors:  Hui-Hui Xu; Jun Gan; Dan-Ping Xu; Lu Li; Wei-Hua Yan
Journal:  Front Immunol       Date:  2021-07-01       Impact factor: 7.561

Review 8.  The dual role of HLA-G in cancer.

Authors:  Nathalie Rouas-Freiss; Philippe Moreau; Joel LeMaoult; Edgardo D Carosella
Journal:  J Immunol Res       Date:  2014-03-31       Impact factor: 4.818

9.  HLA-G dimers in the prolongation of kidney allograft survival.

Authors:  Maureen Ezeakile; Vera Portik-Dobos; Juan Wu; Daniel D Horuzsko; Rajan Kapoor; Muralidharan Jagadeesan; Laura L Mulloy; Anatolij Horuzsko
Journal:  J Immunol Res       Date:  2014-03-30       Impact factor: 4.818

Review 10.  Immunomodulatory properties of HLA-G in infectious diseases.

Authors:  Laurence Amiot; Nicolas Vu; Michel Samson
Journal:  J Immunol Res       Date:  2014-04-15       Impact factor: 4.818
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.